Drug Profile
SPX 601
Alternative Names: SPX-601Latest Information Update: 14 Oct 2021
Price :
$50
*
At a glance
- Originator Seoul Pharma
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Arthritis
Most Recent Events
- 14 Oct 2021 Discontinued - Phase-II for Arthritis in South Korea (unspecified route) (Seoul Pharma Pipeline, October 2021)
- 30 Aug 2018 Phase IIa development is ongoing in South Korea (Seoul Pharma Pipeline, August 2018)
- 09 Oct 2015 Phase-II clinical trials in Arthritis in South Korea (unspecified route)